Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BMY

This Is What Whales Are Betting On Bristol-Myers Squibb

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents

Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents

Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint.

Bristol Myers Squibb Embarks Oncology Pact With Volastra Therapeutics

Bristol Myers Squibb Embarks Oncology Pact With Volastra Therapeutics

Bristol Myers Squibb Co (NYSE: BMY) is pairing with New York-based biotech Volastra Therapeutics.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Wide-Moat Stocks That Look Cheap: Biogen, Medtronic, and Bristol-Myers Squibb

: Major stock indices appear heading for weekly gains with the Fed’s first interest rate hike digested easily by investors. However, the market is expected to remain under pressure in the near term. So, because wide-moat companies generally do well in these market conditions, we think cheap wide-moat stocks Bristol-Myers…

Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit

Bristol Myers Squibb Co (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 study of bempegaldesleukin combined with Opdivo (nivolumab) in previously untreated unresectable or metastatic melanoma patients. The review by an independent Data Monitoring Committee (DMC) suggested that the study did not meet the primary endpoints of…

Bristol Myers Squibb is Soaring, and the Stock is Still Cheap

Bristol Myers Squibb's (BMY) outstanding clinical and operational performance, as well as the current momentum across its product portfolio, have enabled the biopharmaceutical concern to post stable revenue growth in its most recent quarterly earnings release. In addition, the stock is currently trading at a discounted valuation despite generating substantial…

Bristol-Myers Squibb Whale Trades For March 03

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 11 strange trades.

inkl

Read news from The Economist, FT, and more,
with one subscription

4 Red-Hot Value Stocks to Buy This Month

4 Red-Hot Value Stocks to Buy This Month

Investing in fundamentally sound value stocks could be ideal amid surging market volatility, which is due to the rising interest rates, heightened inflation, supply chain disruptions, and an escalating war between Russia and Ukraine. Thus, we think the shares of industry leaders Bristol-Myers (BMY), Lockheed Martin (LMT), Becton Dickinson (BDX),…

Why Bristol Myers' Shares Are Trading Higher Today

Why Bristol Myers' Shares Are Trading Higher Today

Bristol Myers Squibb & Co (NYSE: BMY) has received positive CHMP opinion for Opdivo (nivolumab) plus chemotherapy for first-line treatment of unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Bristol Myers Shares Interim Data From Long-Term Study Of Zeposia In Ulcerative Colitis

Bristol Myers Shares Interim Data From Long-Term Study Of Zeposia In Ulcerative Colitis

Bristol Myers Squibb & Co (NYSE: BMY) has

Bristol-Myers Squibb Whale Trades Spotted

Bristol-Myers Squibb Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Bristol Myers Squibb's Mavacamten Aces Late-Stage Trial In Cardiomyopathy

Bristol Myers Squibb's Mavacamten Aces Late-Stage Trial In Cardiomyopathy

Bristol Myers Squibb Co's (NYSE: BMY) VALOR-HCM Phase 3 study evaluating mavacamten in adults with obstructive hypertrophic cardiomyopathy (obstructive HCM)

Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial

Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL)

Looking At Bristol-Myers Squibb's Recent Whale Trades

Looking At Bristol-Myers Squibb's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 17 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

3 Warren Buffett Stocks to Buy in February: DaVita, Bristol Myers Squibb, and AbbVie

Warren Buffett’s value investing strategy has paid off, as its investment firm Berkshire Hathaway (BRK.A) has outperformed the broader market. Recently, the billionaire has become worther than Meta Platforms (FB) founder Mark Zuckerberg. Hence, we believe that the Berkshire Hathaway holdings AbbVie (ABBV), Bristol-Myers Squibb (BMY), and DaVita (DVA) might…

Bristol Myers Q4 Revenue, FY22 Sales Outlook Lag Consensus

Bristol Myers Squibb & Co (NYSE: BMY) has posted

5 Stocks To Watch For February 4, 2022

Some of the stocks that may grab inve3stor focus today are: Wall Street expects Bristol-Myers Squibb Company (NYSE: BMY) to report quarterly earnings at $1.80 per share on revenue of $12.08 billion after the closing bell. Bristol-Myers Squibb shares rose 0.4% to $64.30 in pre-market trading.

4 Outperforming Value Stocks to Add to Your Portfolio

Because concerns over high inflation and Federal Reserve’s forthcoming interest rate hikes in 2022 have lately driven major benchmark indexes into correction territory, we think it could be wise to bet on value stocks that can dodge the market fluctuations. And Bristol-Myers Squibb (BMY), Lockheed Martin (LMT), Cigna (CI), and…

Get all your
news in one place.

100's of premium titles.
One news app.

1 … 5 6 7 8

People

Mark Zuckerberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Berkshire Hathaway

BristolMyers Squibb

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

397,563 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play